H.B. Fuller Company (FUL) SEC Filings & Earnings Calls
EquiReason read 16 H.B. Fuller Company SEC filings in the last 12 months. Latest: 8-K on 2026-10-22 — Termination of unsecured bridge credit agreement (up to $917M) with no outstanding loans; issuance of $7.625% notes due 2034 under a third supplemental indenture, creating a direct.
Source: SEC EDGAR filings · figures as of 2026-08-31 · read by EquiReason
- Market cap
- 2.7B
- P/E TTM
- 13.8
- Dividend yield
- 1.9%
- 52-week
- —
- Next earnings
- 12 Jan, in 80 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
22 Oct 20268-K · 1.01, 1.02, 2.03Termination of unsecured bridge credit agreement (up to $917M) with no outstanding loans; issuance of $7.625% notes due 2034 under a third supplemental indenture, creating a direct financial obligation.open
Risks flagged
Increased leverage from new note issuance; interest expense will rise due to 7.625% coupon.
“Issuance of $7.625% notes due 2034 increases fixed-charge obligations.”
19 Oct 20268-K · 8.01Board rejected unsolicited proposal to sell Building Adhesive Solutions business; will conduct market check for select segments/product lines.open
Risks flagged
Potential disruption from strategic review and market check; uncertainty around future of Building Adhesive Solutions business.
“Board rejected unsolicited proposal; will conduct market check involving select market segments and product lines.”
9 Oct 20268-K · 8.01H.B. Fuller priced $850M of 7.625% senior unsecured notes due 2034 in a private offering under Rule 144A/Reg S.open
Risks flagged
High interest expense from 7.625% coupon may pressure net income and cash flow.
“7.625% interest rate on $850M notes”
6 Oct 20268-K · 7.01H.B. Fuller files pro forma financial information in connection with a pending offering of notes to finance the acquisition of AMS (a UK-based company). Pro forma net secured leverage ratio 2.5x, net total leverage 4.2x.open
Figures in the filing · each found in the filing text
| Pro forma net secured leverage ratio · twelve_months_en | $2.50 | |
| Pro forma net total leverage ratio · twelve_months_en | $4.20 | |
| Pro forma interest coverage ratio · twelve_months_en | $3.30 | |
| Pro forma net revenue · twelve_months_en | $3.87B | |
| Pro forma net income · twelve_months_en | $100M | |
| Pro forma adjusted EBITDA · twelve_months_en | $713M |
Risks flagged
Increased leverage post-acquisition; pro forma net total leverage at 4.2x and interest coverage at 3.3x.
“Pro forma net total leverage ratio 4.2x; pro forma interest expense $217,701.”
Integration risk for AMS acquisition; pro forma adjustments include significant amortization and interest expense.
“Pro forma adjustments include amortization of intangible assets and additional interest expense from acquisition financing.”
24 Sep 202610-QH.B. Fuller reported Q3 2026 revenue up 5.2% YoY, gross margin +120bps, and adjusted EBITDA +9.4%, but volume declined 3%.earningsopen
Figures in the filing · each found in the filing text
| Net revenue · Q3-2026 | $938M | +5% y/y |
| Gross profit margin · Q3-2026 | 33.2% | |
| Adjusted EBITDA · Q3-2026 | $187M | +9% y/y |
| Adjusted EBITDA margin · Q3-2026 | 19.9% | |
| Net income attributable to H.B. Fuller · Q3-2026 | $79M | +18% y/y |
| Diluted earnings per share · Q3-2026 | $1.44 | +18% y/y |
| Free cash flow · H1-2026 | $41M | -34% y/y |
| Total debt to total capital ratio · 2026-08-29 | 48.7% | |
| Hygiene, Health and Consumable Adhesives net revenue · Hygiene, Health and Consumable Adhesives · Q3-2026 | $413M | +7% y/y |
| Engineering Adhesives net revenue · Engineering Adhesives · Q3-2026 | $279M | +2% y/y |
Risks flagged
Shareholder activism distraction
“Shareholder activism efforts could be disruptive and costly and may create uncertainty regarding our strategic direction.” · word for word
Volume decline persists
“partially offset by a 3.0 percent decrease due to sales volume compared to the third quarter of 2025.” · word for word
Higher interest expense
“Interest expense in the third quarter of 2026 was $40.9 million compared to $33.6 million in the third quarter of 2025 primarily due to higher debt levels and debt extinguishment costs.” · word for word
24 Sep 20268-K · 2.02H.B. Fuller reports Q3 2026: revenue $938M (+5.2% YoY), adj. EBITDA $187M (+9% YoY), adj. EPS $1.52 (+21% YoY), adj. EBITDA margin 19.9% (+80bps YoY). Guidance raised: adj. EBITDA $655-670M, adj. EPS $4.70-4.85.earningsopen
Figures in the filing · each found in the filing text
| Net revenue · Q3-2026 | $938M | +5% y/y |
| Organic revenue growth · Q3-2026 | 4.4% | |
| Net income · Q3-2026 | $79M | |
| Adjusted EBITDA · Q3-2026 | $187M | +9% y/y |
| Adjusted EBITDA margin · Q3-2026 | 19.9% | |
| Reported EPS (diluted) · Q3-2026 | $1.44 | |
| Adjusted EPS (diluted) · Q3-2026 | $1.52 | +21% y/y |
| Gross margin · Q3-2026 | 33.2% | |
| Adjusted gross margin · Q3-2026 | 33.5% | |
| Net debt · Q3-2026 | $1.96B |
Guidance
FY26 adjusted EBITDA raised to $655-670M; FY26 adjusted EPS raised to $4.70-4.85; FY26 core tax rate 25.5-26.0%; FY26 cash flow from operations $300-325M (excl. AMS); FY26 net revenue still up mid-single digits; organic revenue still up low-single digits; pricing up mid-single digits; volume down low-single digits; FX impact ~2%.
Guidance raised for adjusted EBITDA and adjusted EPS; revenue outlook maintained; margin expansion trajectory continues.
Risks flagged
Middle East disruption impacting supply chain; strategic inventory build increases working capital.
“strategic inventory investments to support Quantum Leap and ensure supply continuity for customers amid ongoing disruption in the Middle East” · word for word
Volume decline (low-single digits) partially offsetting pricing gains.
“volume down low-single digits” · word for word
Higher raw material costs requiring pricing actions to offset.
“Pricing actions are offsetting higher raw material costs” · word for word
20 Jul 20268-K · 1.01, 1.02, 2.03H.B. Fuller amended credit agreement: refinanced $420M term loans, increased revolver to $800M, extended maturity to 2031, reduced margins by 25bps.open
Risks flagged
No material risk identified; amendment improves terms.
26 Jun 20268-K · 1.01, 2.03, 7.01H.B. Fuller entered a secured bridge credit agreement with Goldman Sachs to finance acquisition of Advanced Medical Solutions Group PLC; creates direct financial obligation.open
Risks flagged
Increased leverage from bridge financing; integration risk of acquired entity.
“Creation of direct financial obligation; secured bridge credit agreement.”
25 Jun 20268-K · 2.02Net revenue $950M (+6% y/y); Adjusted gross profit margin 34.2; Adjusted EBITDA $181M (+9% y/y); Guidance: Adj. EBITDA $650-675M (prev. ~$640-665M); adj. EPS $4.60-4.90 (prev. ~$4.40-4.70)earningsopen
Figures in the filing · each found in the filing text
| Net revenue · Q2-2026 | $950M | +6% y/y |
| Adjusted gross profit margin · Q2-2026 | 34.2% | |
| Adjusted EBITDA · Q2-2026 | $181M | +9% y/y |
| Adjusted EPS (diluted) · Q2-2026 | $1.41 | +19% y/y |
| Operating cash flow · Q2-2026 | $121M | +10% y/y |
| Net debt · Q2-2026 | $1.96B |
Guidance
Adj. EBITDA $650-675M (prev. ~$640-665M); adj. EPS $4.60-4.90 (prev. ~$4.40-4.70)
Raised full-year adj. EBITDA and adj. EPS guidance; Q3 guidance provided; strong execution.
Risks flagged
Volume slightly lower; dynamic external environment; foreign exchange impact.
“Slightly lower volume; foreign currency translation impact of 3.1%; 'external environment remains dynamic'.”
25 Jun 202610-QNet revenue $950M (+6% y/y); Net income attributable to H.B. Fuller $68M (+62% y/y); Free cash flow $13M (+291% y/y)open
Figures in the filing · each found in the filing text
| Net revenue · Q2-2026 | $950M | +6% y/y |
| Net income attributable to H.B. Fuller · Q2-2026 | $68M | +62% y/y |
| Free cash flow · 6M-2026 | $13M | +291% y/y |
| Net cash provided by operating activities · 6M-2026 | $117M | +103% y/y |
| Diluted earnings per share · Q2-2026 | $1.23 | +62% y/y |
| Organic revenue growth · Q2-2026 | 2.6% | |
| Pricing impact on revenue · Q2-2026 | 3.0% | |
| Volume impact on revenue · Q2-2026 | -0.4% | |
| Currency impact on revenue · Q2-2026 | 3.1% |
Risks flagged
Volume decline in Engineering Adhesives
“Engineering Adhesives organic revenue declined 1.0% in Q2, driven by volume decline, indicating potential demand weakness in industrial end markets.”
Higher manufacturing and distribution costs
“Other manufacturing costs as a percentage of net revenue increased 60 basis points in Q2 due to higher manufacturing and distribution costs.” · word for word
26 Mar 202610-QH.B. Fuller reported Q1 FY2026 results with a decline in organic revenue due to lower volume, but significant margin expansion and earnings growth.earningsopen
Figures in the filing · each found in the filing text
| Net revenue · Q1-2026 | $771M | -2% y/y |
| Net income attributable to H.B. Fuller · Q1-2026 | $21M | +59% y/y |
| Adjusted EBITDA · Q1-2026 | $119M | +4% y/y |
| Gross profit · Q1-2026 | $236M | +4% y/y |
| Net cash provided by (used in) operating activities · Q1-2026 | $-4M | +93% y/y |
| Free cash flow · Q1-2026 | $-62M | +28% y/y |
| Hygiene, Health and Consumable Adhesives revenue · Hygiene, Health and Consumable Adhesives · Q1-2026 | $347M | -6% y/y |
| Engineering Adhesives revenue · Engineering Adhesives · Q1-2026 | $242M | +2% y/y |
| Building Adhesive Solutions revenue · Building Adhesive Solutions · Q1-2026 | $182M | -1% y/y |
| Cash and cash equivalents · Q1-2026 | $108M | +2% y/y |
Risks flagged
Demand Weakness / Volume Decline
“Organic revenue decreased 6.6 percent in the first quarter of 2026 compared to the first quarter of 2025... driven by a 7.2 percent decrease in sales volume.” · word for word
Asbestos Litigation Exposure
“We have been named as a defendant in lawsuits in which plaintiffs have alleged injury due to products containing asbestos manufactured more than 35 years ago.” · word for word
Rouse et al. Settlement
“The Company and the plaintiffs agreed in principle to settle this matter for up to $75.0 million... recorded an accrual in anticipation of the settlement of $34.8 million ($26.3 million after tax).” · word for word
High Leverage
“Total debt to total capital ratio 50.1 percent as of February 28, 2026.”
Restructuring Execution Risk
“During the first quarter of 2026, the Company approved other restructuring actions related to global footprint optimization... currently expected to be completed during fiscal year 2028.” · word for word
26 Mar 20268-K · 2.02Net revenue $771M (-2% y/y); Adjusted EBITDA $119M (+4% y/y); Adjusted EPS (diluted) $0.57 (+6% y/y); Guidance: Revenue up mid-single digits; Adjusted EBITDA $645M-$675M; Adjusted EPS $4.55-$4.90earningsopen
Figures in the filing · each found in the filing text
| Net revenue · Q1-2026 | $771M | -2% y/y |
| Adjusted EBITDA · Q1-2026 | $119M | +4% y/y |
| Adjusted EPS (diluted) · Q1-2026 | $0.57 | +6% y/y |
| Adjusted gross margin · Q1-2026 | 31.3% | |
| Adjusted EBITDA margin · Q1-2026 | 15.4% | |
| Net income · Q1-2026 | $21M | |
| Net debt · Q1-2026 | $1.97B | -5% y/y |
| Net debt-to-adjusted EBITDA · Q1-2026 | $3.10 |
Guidance
Revenue up mid-single digits; Adjusted EBITDA $645M-$675M; Adjusted EPS $4.55-$4.90
Raised full-year guidance on revenue, EBITDA, and EPS despite organic volume decline; margin expansion from restructuring and pricing actions
Risks flagged
Geopolitical instability in Middle East adding supply chain complexity and cost
“the geopolitical instability in the Middle East adds significant complexity, disruption, and cost to global supply chains” · word for word
Volume decline of 6.6% organic revenue indicates demand weakness
“organic revenue was down 6.6% year-on-year” · word for word
4 Mar 2026DEF 14AH.B. Fuller filed its definitive proxy statement for the 2026 annual meeting, disclosing executive compensation, governance, and financial performance.open
Figures in the filing · each found in the filing text
| Net revenue · FY2025 | $3.47B | |
| Net income · FY2025 | $152M | |
| Adjusted EBITDA · FY2025 | $621M | |
| Adjusted EBITDA Margin · FY2025 | 17.9% | |
| Adjusted EPS · FY2025 | $4.24 | |
| Operating cash flow · FY2025 | $263M | |
| EPS · FY2025 | $2.75 | |
| Hygiene, Health and Consumable Adhesives segment revenue · Hygiene, Health and Consumable Adhesives · FY2025 | $1.55B | +0% y/y |
| Engineering Adhesives segment revenue · Engineering Adhesives · FY2025 | $1.06B | +5% y/y |
| Building Adhesive Solutions segment revenue · Building Adhesive Solutions · FY2025 | $860M | +0% y/y |
22 Jan 202610-KNet Revenue $2.00B; Raw Material Cost as % of COGS 75; Raw Material Spend $1.70Bopen
Figures in the filing · each found in the filing text
| Net Revenue · FY2025 | $2.00B | |
| Raw Material Cost as % of COGS · FY2025 | 75.0% | |
| Raw Material Spend · FY2025 | $1.70B | |
| Restructuring Costs Incurred · FY2025 | $79M | |
| Project ONE Expenditures · FY2025 | $265M |
Risks flagged
Raw Material Cost Volatility
“In 2025, raw material costs made up approximately 75 percent of our cost of sales. ... a hypothetical one percent change in our raw material costs would have resulted in a change in net income of approximately $12.6 million or $0.23 per diluted share.” · word for word
Foreign Exchange Exposure
“Approximately 56 percent, or $2.0 billion, of our net revenue was generated outside the United States in 2025.”
Tariff and Trade Policy Risk
“Import tariffs, taxes, customs duties and other trading regulations imposed by the U.S. government on foreign countries, or by foreign countries on the U.S., could significantly increase the prices we pay for raw materials that are critical to our ability to manufacture our products.” · word for word
ERP Implementation Risk
“Any delays or other failure to achieve our implementation goals may adversely impact our financial results.” · word for word
Competition
“Many of our direct competitors are part of large multinational companies and may have more resources than we do.” · word for word
15 Jan 20268-K · 2.02Net revenue $895M (-3% y/y); Adjusted EBITDA $170M (+15% y/y); Adjusted EBITDA margin 19; Guidance: FY2026 adjusted EBITDA $630M-$660M; adjusted EPS $4.35-$4.70earningsopen
Figures in the filing · each found in the filing text
| Net revenue · total · Q4-2025 | $895M | -3% y/y |
| Adjusted EBITDA · total · Q4-2025 | $170M | +15% y/y |
| Adjusted EBITDA margin · total · Q4-2025 | 19.0% | |
| Adjusted EPS (diluted) · total · Q4-2025 | $1.28 | +39% y/y |
| Full Year Adjusted EBITDA · total · FY2025 | $621M | +5% y/y |
Guidance
FY2026 adjusted EBITDA $630M-$660M; adjusted EPS $4.35-$4.70
FY2026 guidance implies continued margin expansion toward >20% EBITDA margin target.
Risks flagged
Challenging demand environment with volume decline; tariff costs impacting gross margin.
“Organic revenue was down 1.3% year-on-year, with volume decreasing organic revenue by 2.5%.” · word for word
H.B. Fuller Company — questions
- What did H.B. Fuller Company file recently?
- 16 SEC filings in the last 12 months. Latest: 8-K on 2026-10-22 — Termination of unsecured bridge credit agreement (up to $917M) with no outstanding loans; issuance of $7.625% notes due 2034 under a third supplemental indenture, creating a direct financial obligation.
Every figure on this page comes from H.B. Fuller Company's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.